Unique Wealth LLC Sells 3,518 Shares of Stryker Corporation $SYK

Unique Wealth LLC trimmed its stake in shares of Stryker Corporation (NYSE:SYK) by 53.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,069 shares of the medical technology company’s stock after selling 3,518 shares during the quarter. Unique Wealth LLC’s holdings in Stryker were worth $1,008,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the 4th quarter valued at $26,000. Sankala Group LLC acquired a new position in Stryker during the fourth quarter worth $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the third quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker during the fourth quarter valued at $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker in the 4th quarter valued at $28,000. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of SYK stock opened at $316.41 on Friday. The stock’s fifty day moving average is $311.29 and its 200-day moving average is $339.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The stock has a market capitalization of $121.30 billion, a PE ratio of 36.62, a PEG ratio of 2.01 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the company earned $2.84 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analysts Set New Price Targets

Several research firms have recently weighed in on SYK. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Wells Fargo & Company decreased their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Finally, BTIG Research cut their target price on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.